2016 Annual Report on Prostate Diseases

Most men eventually develop some type of prostate problem, and when they do there are usually no easy solutions. More than a primer on prostate conditions, the Annual Report on Prostate Diseases includes roundtable discussions with experts at the forefront of prostate research, interviews with men about their treatment decisions, and the latest thinking on complementary therapies. This report will provide you with the information you need to understand the current controversies, avoid common pitfalls, and work with your doctor to make informed choices about your prostate health.

2016 Annual Report on Prostate Diseases  Cover

What to do about Erectile Dysfunction

With all the ads on TV and in magazines heralding pills to treat erectile dysfunction (ED), it’s tempting to think that treatment for ED begins and ends with Viagra, Levitra, and Cialis. But it’s important to be aware that many men can ease, or even reverse, ED by making simple lifestyle changes — such as losing excess weight and quitting smoking — that also are likely to boost their overall health and reduce their chances…

Learn More »

Most men eventually develop some type of prostate problem, and when they do there are usually no easy solutions. The three most common prostate problems are benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. Men with the same condition and symptoms might opt for very different treatments — or choose to do nothing at all.

Right now, one of the major controversies in prostate treatment involves the PSA test that is used for routine screening. This report explains why the test has fallen into disfavor and provides crucial information on how to proceed if your test results are abnormal. It also discusses the increasing use of active surveillance — a monitoring strategy that allows men with low-risk prostate cancer to delay and perhaps avoid treatment altogether — and intermediate treatment strategies for those who aren’t comfortable forgoing therapy. Plus you’ll learn about emerging tests — so called biomarkers and even genetic based tests.

You’ll be briefed on the latest treatments that address “going” and “growing”, an outpatient laser procedure that is gaining in popularity over the traditional “roto-rooter”techniques. You will read about advances in prostate cancer treatment that are minimizing side effects, increasing longevity, and dramatically preserving — and improving — quality of life. You’ll learn about the
risks and rewards of “active surveillance”, the controversial role of robotic-surgery, and more. Plus, the report will update you on treatment options for prostatitis, a medication for difficult-to treat erectile problems after prostate cancer surgery, and lifestyle changes that can improve health and lower the risk of developing prostate disease.

That’s why this unique publication is more than a primer on prostate conditions; it includes roundtable discussions with experts at the forefront of prostate research, interviews with patients about their treatment decisions, and the latest thinking on complementary therapies.

The goal of this publication is not to relate easy answers. Rather, our mission is to provide you with the information you need to understand the current controversies, avoid common pitfalls, and work with your doctor to make informed choices about your prostate health.

Prepared by the editors of Harvard Health Publications in consultation with Marc B. Garnick, M.D., Clinical Professor of Medicine, Harvard Medical School, and Hematology/Oncology Division, Beth Israel Deaconess Medical Center. 124 pages. (2016)

  • Monitoring prostate health
    • Digital rectal examination
    • Prostate-specific antigen (PSA) test
    • Other PSA tests
    • Other tests in development  
    • Ultrasound  
    • Magnetic resonance imaging (MRI)  
    • Positron emission tomography (PET) scans  
    • Prostate biopsy  
  • Prostate cancer
    • What causes prostate cancer?
    • Risk factors
    • Can prostate cancer be prevented?
    • Diagnosis and prognosis  
    • Treating prostate cancer
    • Active surveillance
    • Surgery
    • Radiation therapy
    • Focal therapy
    • Hormone therapy
    • Chemotherapy
    • Drugs in development
    • Vaccines and other types of immunotherapy
  • An international perspective
    • Multivitamins don’t protect against prostate cancer
    • Physicians support active surveillance but don’t recommend it
    • Men least likely to benefit are receiving prostate cancer treatment
    • Study helps better determine when postoperative radiation improves outcomes
    • Protecting bones while treating advanced prostate cancer
    • Clues that a diabetes drug may fight prostate cancer
  • Prostate enlargement (benign prostatic hyperplasia)
    • How BPH progresses  
    • Getting help  
    • Treating BPH
  • Inflammation of the prostate (prostatitis)
    • What is prostatitis?  
    • Diagnosing prostatitis
    • Treating prostatitis
  • Erectile dysfunction and urinary incontinence
    • Treating erectile dysfunction  
    • Treating urinary incontinence  
  • Take charge of your condition
    • Participate in a clinical trial
    • Join a support group
    • Eat a healthy diet
    • Lose weight  
    • Exercise more  
    • Consider complementary and contemplative therapies
  • Searching PubMed in five easy steps
  • Resources
    • Organizations  
    • Publications
  • Glossary
  • Related publications from Harvard Medical School

Time to develop your own game plan

This report is published each year around the time of the NFL playoffs. And if you’re a football fan, as I am, it’s hard to escape the steady barrage of ads for drugs to treat benign prostatic hyperplasia (BPH) and erectile dysfunction, or the celebrity pitches urging men to undergo PSA screening for prostate cancer.

It can be overwhelming. That’s why this publication is intended to help you become the quarterback when it comes to treatment decisions about BPH, prostatitis, erectile dysfunction, and other common prostate problems. And if I can stretch the football analogy a little further, I’d like to call for a whole new game plan when it comes to diagnosing and treating prostate cancer.

Research published over the past year has made it even more evident that widespread PSA screening is detecting cancers at such an early stage that it is doing more harm than good. In May, the U.S. Preventive Services Task Force recommended against prostate-specific antigen (PSA) screening for any man, regardless of age, race, or family history—arguing that for most men screening does not save lives and causes serious and long-lasting harms. Certainly the consensus has been building in this direction for quite a while, but the USPSTF is one of the nation’s most authoritative voices on this matter. Meanwhile, a long-awaited American study, the Prostate Cancer Intervention Versus Observation Trial (PIVOT), concluded that men who underwent surgery for localized prostate cancer were no more likely to survive than those who avoided treatment.

But it wasn’t all bad news. Several new drugs for late-stage prostate cancer have come on the market, and others are far along in the pipeline. These developments have helped to redefine metastatic disease from a death sentence to a condition men can live with—often for years, and without the disabling pain and crippling bone problems of the past.

That’s why this unique publication is more than a primer on prostate conditions; it includes insights from experts at the forefront of prostate research, interviews with patients about their treatment decisions, and the latest thinking about diet and complementary therapies. The companion website, www.HarvardProstateKnowledge.org, offers additional features and research updates throughout the year.

The goal of this publication is not to relate easy answers—because in many instances there are none. Rather, our mission is to provide you with the information you need to understand the current controversies, avoid common pitfalls, and work with your doctor to make informed choices about your prostate health.

No reviews have been left for this this report. Log in and leave a review of your own.